migraine treatment
Japan’s Shin Nippon Biomedical Labs to buy US-based Satsuma for nasal powder migraine drug
Developed by Satsuma, STS101 is a nasal powder formulation of the anti-migraine drug, dihydroergotamine mesylate.
Japan’s Shin Nippon Biomedical Labs to buy US-based Satsuma for nasal powder migraine drug
Developed by Satsuma, STS101 is a nasal powder formulation of the anti-migraine drug, dihydroergotamine mesylate.
Drug approvals boost Japanese migraine treatment online
Some players have been highly active in digital channels of various countries.
Most Read
1. Here are top three medical conditions driving medical plan costs 2. Majority of doctors in Southeast Asia ride the digital shift: study 3. Smart hospital beds market’s CAGR to grow 14% from 2022 to 2030 4. Bumrungrad and BDMS to benefit from Thai strong medical tourism 5. Healthcare businesses urged to address these five AI risksResource Center
Read Here
Advertise
Sign Up
Awards
Event News
Event News
Healthcare Asia Awards 2023 Winner: Thomson Hospital Kota Damansara
![Healthcare Asia Awards 2023 Winner: Thomson Hospital Kota Damansara]()
Thomson Hospital Kota Damansara claims the coveted title of Allied Health Initiative of the Year - Malaysia at the Healthcare Asia Awards 2023
Healthcare Asia Awards 2023 Winner: Thomson Hospital Kota Damansara
Thomson Hospital Kota Damansara claims the coveted title of Allied Health Initiative of the Year - Malaysia at the Healthcare Asia Awards 2023
